Updated:
Zentynel Frontier Investments
Zentynel Frontier Investments launched as a venture capital firm in Santiago, Chile, built on a joint vision between Fundación Ciencia & Vida and...
Zentynel Frontier Investments
Zentynel Frontier Investments launched as a venture capital firm in Santiago, Chile, built on a joint vision between Fundación Ciencia & Vida and Venturance Alternative Assets. General Partner Cristián Hernández, a two-decade veteran of biotech investing and company building, leads a model designed to bridge the region’s persistent gap in biotech venture funding with capital, scientific knowledge, and direct operational support for founders. The firm runs a stage-agnostic early-entry strategy, writing first checks of US$1 million to US$2 million into startups with strong Latin American ties and reserving 25–30% of each fund for follow-on rounds. Portfolio positions span human and animal health — pharmaceuticals, vaccines, diagnostics — alongside digital-health platforms, agtech, foodtech, and environmental biotechnology, with confirmed investments in Momentum Therapeutics (brain-aging therapies, operating in Chile and the US), Neocrop Technologies (gene-edited crop development, Chile and US), and HeXemBio (cellular rejuvenation, US and Brazil). Geography follows scientific talent, with active companies in Chile, Argentina, Brazil, Uruguay, Mexico, Colombia, the US, and Europe. Fund I backed 17 companies across six countries and catalyzed more than US$100 million in co-investment, while Fund II targets US$50 million exclusively for biotech and health-tech. The full team size and additional office locations are not publicly disclosed. In May 2026, Cristián Hernández published a position paper titled “The New Operating System of Biotech,” outlining the thesis that Latin America’s talent depth, biodiversity, and cost advantages offer an undercapitalized edge in the next industrial convergence of biotech with AI and automation. Zentynel’s architecture unites a non-profit research foundation with an alternatives asset manager, creating a deal-sourcing and diligence engine uncommon in Latin American venture. Founders get activated support — regulatory science guidance, international network access, and operational counsel — from a firm that does not merely allocate but co-builds, a posture that positions Zentynel as an early mover while the region’s biotech ecosystem remains institutionally thin.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed (Altss estimate)
Location
Region
Latin America
Country
Chile
City
Santiago
Corporate office
Santiago, Chile
Principals
Cristián Hernández
General Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Zentynel Frontier Investments?
Cristián Hernández leads the firm as General Partner, bringing over twenty years of experience investing in and building biotech companies. He has served as CEO or director of multiple biotech ventures and research centers, including Fundación Ciencia & Vida, Nova Mineralis, Ingalfarma, and Phage Labs (per firm website). The full composition of the investment committee beyond Hernández is not publicly detailed.
How is Zentynel structured — is it a single-family office or a traditional venture fund?
Zentynel operates as a dedicated venture capital fund manager, not a family office, raising committed capital from external limited partners. It was co-founded by Fundación Ciencia & Vida, a non-profit research institute, and Venturance Alternative Assets, an alternatives manager, combining scientific origination with fund-management discipline. The firm manages successive blind-pool venture funds typical of an institutional GP structure.
Does Zentynel participate in fund commitments or only direct deals?
Zentynel invests exclusively via direct equity in early-stage operating companies. There is no public evidence of fund-of-fund commitments or LP positions in external venture managers. The model is defined by principal investments with active board-level and operational engagement.
What investment stages and check sizes does Zentynel target?
The firm targets early-stage opportunities, typically writing initial checks between US$1 million and US$2 million. It reserves 25–30% of each fund for follow-on investments to support portfolio companies through subsequent financing rounds (per firm website).
Which sectors does Zentynel explicitly avoid?
Zentynel focuses exclusively on biotech and health-tech; publicly available portfolio data shows no investments outside human health, animal health, agtech, foodtech, or digital-health platforms. Sectors such as enterprise software, fintech, or industrial tech fall outside its mandate.
What is Zentynel's geographic investment footprint?
Portfolio companies originate from Chile, Argentina, Brazil, Uruguay, Mexico, Colombia, the United States, and Europe, reflecting a Latin America-plus strategy that seeks founding teams with regional scientific roots and global commercial ambition. The firm itself is managed from Santiago, Chile.
How is Zentynel related to Fundación Ciencia & Vida?
Fundación Ciencia & Vida is one of the two founding entities behind Zentynel, contributing deep scientific networks and domain expertise that anchor the fund's deal sourcing and technical diligence. Venturance Alternative Assets provides the fund management and alternatives-investing infrastructure. The fund operates independently as an investment manager, drawing on the foundation for non-commercial scientific advisory capacity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: